The primary goal of this clinical trial is to test the hypothesis that the drug canakinumab (anti-IL-1B monoclonal antibody) decreases vascular inflammation wh…

Vascular InflammationASCVDASCVD Management

~Estimated

~$10 – $6,250

Massachusetts General HospitalNCT06691217

Using Pharmacy Extenders to Optimize Non-statin Agents for Secondary ASCVD Prevention Outcomes in a Federally Qualified Health Center

* The purpose of the study is to improve care for patients with high cholesterol. * If you choose to join the study, you will be asked to answer a phone call f…

ASCVD Management

~Estimated

~$10 – $750

University of Texas at AustinNCT07464574

Phase 2

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy, Safety, and Population Pharmacokinetics (PopPK) Profile of ABP-745 in Patients With Atherosclerosis

This is a multicenter, randomized, double-blind, placebo parallel controlled study to evaluate the preliminary efficacy, safety, and PopPK profile of ABP-745 i…

Atherosclerosis Cardiovascular DiseaseASCVDASCVD Management

~Estimated

~$10 – $8,750

Atom Therapeutics Co., LtdNCT07303777